Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3677899 | 0.92 | GAA (0.41) | GAAMAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL6730444 | 0.92 | MAPT (0.39) | GAAMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL12064247 | 0.91 | MAPT (0.38) | GAAMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL1656717 | 0.91 | MET (0.42) | GAAMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL1301071 | 0.91 | MAPT (0.38) | GAAMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL1497638 | 0.91 | MAPT (0.39) | GAAMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL2258176 | 0.90 | GAA (0.36) | GAAMAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1658265 | 0.90 | MAPT (0.38) | GAAMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL24632272 | 0.89 | MET (0.38) | MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL1656711 | 0.89 | MAPT (0.36) | MAPTALDH1A1SMN1; SMN2MAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3843743-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | Bayer AS (NO) | 2021-07-07 | — | — | EP | claimed |
| US-20210187134-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | BAYER AS (NO) | 2021-06-24 | — | — | US | claimed |
| WO-2020164997-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-20 | — | — | WO | claimed |
| WO-2020043617-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | BAYER AS (NO) | 2020-03-05 | — | — | WO | claimed |
| US-20190255063-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-22 | — | — | US | claimed |
| EP-3515911-A1 | COMBINATION OF PI3K-INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2019-07-31 | — | — | EP | claimed |
| EP-2983669-B1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES FOR TREATING LYMPHOMAS | Bayer Pharma AG (DE) | 2018-10-24 | — | — | EP | claimed |
| US-RE46856-E1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-05-22 | — | — | US | claimed |
| WO-2018054782-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-03-29 | — | — | WO | claimed |
| US-20180042929-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-02-15 | — | — | US | claimed |
| EP-2694069-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | Bayer Pharma Aktiengesellschaft (DE) | 2014-02-12 | — | — | EP | claimed |
| US-20130261113-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION | 2013-10-03 | — | — | US | claimed |
| US-8466283-B2 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-18 | — | — | US | claimed |
| WO-2012136549-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-11 | — | — | WO | claimed |
| US-20110251191-A1 | USE OF SUBSTITUTED 2, 3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES FOR THE TREATMENT OF MYELOMA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-13 | — | — | US | claimed |
| EP-2344164-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES FOR THE TREATMENT OF MYELOMA | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-07-20 | — | — | EP | claimed |
| US-20110083984-A1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-14 | — | — | US | claimed |
| WO-2010034414-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES FOR THE TREATMENT OF MYELOMA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-01 | — | — | WO | claimed |
| EP-2168582-A1 | Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | claimed |
| EP-2168583-A1 | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261113-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | PIK3CA, PIK3CD, PIK3CB | GAA 809/4885MAPT 2883/4885ALDH1A1 4032/4885 |
| US-20210187134-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | PIK3CA, PIK3CD, PIK3CB | GAA 522/4885MAPT 844/4885ALDH1A1 4419/4885 |
| US-20180042929-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | PIK3R4, PIK3R5, PIK3C2B | GAA 3978/4885MAPT 4578/4885ALDH1A1 2670/4885 |
| US-20190255063-A1 | COMBINATION OF PI3K-INHIBITORS | BCL9L, BCL9, MALT1 | GAA 3097/4885MAPT 4487/4885ALDH1A1 4001/4885 |
| US-20110251191-A1 | USE OF SUBSTITUTED 2, 3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES FOR THE TREATMENT OF MYELOMA | MCL1, BCL9, BCL3 | GAA 2276/4885MAPT 4623/4885ALDH1A1 1389/4885 |
| US-20110083984-A1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | PIK3CA, PIK3CD, PIK3CB | GAA 809/4885MAPT 2883/4885ALDH1A1 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.